dapsone has been researched along with Infection, Toxoplasma gondii in 20 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Dapsone alone was not as good as either of the other two drugs tested." | 5.24 | Sulphadimidine, pyrimethamine and dapsone in the treatment of toxoplasmosis in mice. ( BEVERLEY, JK; FRY, BA, 1957) |
| " For dapsone, among 100 patients given 100 mg daily instead of twice a week for 1 year (primary prophylaxis), seven fewer patients would develop P carinii pneumonia, but 17 more would have significant toxic reactions." | 4.79 | A meta-analysis of the relative efficacy and toxicity of Pneumocystis carinii prophylactic regimens. ( Cappelleri, JC; Ioannidis, JP; Lau, J; Sacks, HS; Skolnik, PR, 1996) |
| "In a meta-analysis, we examined the efficacy of aerosolized pentamidine, trimethoprim-sulfamethoxazole, and dapsone or dapsone/pyrimethamine for the prevention of Pneumocystis carinii pneumonia and toxoplasma encephalitis in patients with HIV infection." | 4.79 | Meta-analysis of prophylactic treatments against Pneumocystis carinii pneumonia and toxoplasma encephalitis in HIV-infected patients. ( Bucher, HC; Griffith, L; Guyatt, GH; Opravil, M, 1997) |
| " Overall results from these studies indicate patients who are eligible for PCP prophylaxis should be advised to take double-strength trimethoprim/sulfamethoxazole (TMP/SMX) on a daily basis, a dosage found more effective than thrice-weekly." | 1.30 | Optimizing PCP therapy. ( Cadman, J; Torres, G, 1997) |
| " Within a short time of dosing such animals, there is little or none of the uncombined drug in the blood." | 1.24 | The treatment of experimental toxoplasmosis in rabbits. ( BEVERLEY, JK; FRY, BA, 1957) |
| "Dapsone alone was not as good as either of the other two drugs tested." | 1.24 | Sulphadimidine, pyrimethamine and dapsone in the treatment of toxoplasmosis in mice. ( BEVERLEY, JK; FRY, BA, 1957) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 6 (30.00) | 18.7374 |
| 1990's | 13 (65.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (5.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Wozel, VE | 1 |
| BEVERLEY, JK | 2 |
| FRY, BA | 2 |
| GARIN, JP | 1 |
| POTTON, F | 1 |
| CROSS, JB | 2 |
| Podzamczer, D | 2 |
| Salazar, A | 1 |
| Jiménez, J | 2 |
| Consiglio, E | 1 |
| Santín, M | 2 |
| Casanova, A | 2 |
| Rufí, G | 1 |
| Gudiol, F | 1 |
| Oksenhendler, E | 1 |
| Charreau, I | 1 |
| Tournerie, C | 1 |
| Azihary, M | 1 |
| Carbon, C | 1 |
| Aboulker, JP | 1 |
| Bolao, F | 1 |
| Gudiol, GR | 1 |
| Opravil, M | 2 |
| Keusch, G | 1 |
| Lüthy, R | 1 |
| Ioannidis, JP | 1 |
| Cappelleri, JC | 1 |
| Skolnik, PR | 1 |
| Lau, J | 1 |
| Sacks, HS | 1 |
| Bucher, HC | 1 |
| Griffith, L | 1 |
| Guyatt, GH | 1 |
| Sackoff, J | 1 |
| McFarland, J | 1 |
| Su, S | 1 |
| Bryan, E | 1 |
| Payen, MC | 1 |
| De Wit, S | 1 |
| Sommereijns, B | 1 |
| Clumeck, N | 1 |
| Cheng, B | 1 |
| Torres, G | 1 |
| Cadman, J | 1 |
| Hardy, WD | 2 |
| Clotet, B | 1 |
| Sirera, G | 1 |
| Romeu, J | 1 |
| Gimeno, JM | 1 |
| Jou, A | 1 |
| Condom, MJ | 1 |
| Tor, J | 1 |
| Foz, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effect of Fluconazole, Clarithromycin, and Rifabutin on the Pharmacokinetics of Sulfamethoxazole and Dapsone and Their Hydroxylamine Metabolites[NCT00000826] | Phase 1 | 48 participants | Interventional | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 reviews available for dapsone and Infection, Toxoplasma gondii
| Article | Year |
|---|---|
A meta-analysis of the relative efficacy and toxicity of Pneumocystis carinii prophylactic regimens.
Topics: AIDS-Related Opportunistic Infections; Dapsone; Dose-Response Relationship, Drug; Humans; Logistic M | 1996 |
Meta-analysis of prophylactic treatments against Pneumocystis carinii pneumonia and toxoplasma encephalitis in HIV-infected patients.
Topics: Administration, Inhalation; AIDS-Related Opportunistic Infections; Anti-Infective Agents; Antifungal | 1997 |
Prophylaxis of AIDS-related opportunistic infections (OIs). Current status and future strategies.
Topics: Acquired Immunodeficiency Syndrome; Aerosols; Animals; Cryptococcosis; Cytomegalovirus Infections; D | 1991 |
Prophylaxis of AIDS-related opportunistic infections (OIs).
Topics: Acquired Immunodeficiency Syndrome; Cryptococcosis; Cytomegalovirus Infections; Dapsone; Drug Combin | 1989 |
5 trials available for dapsone and Infection, Toxoplasma gondii
| Article | Year |
|---|---|
Intermittent trimethoprim-sulfamethoxazole compared with dapsone-pyrimethamine for the simultaneous primary prophylaxis of Pneumocystis pneumonia and toxoplasmosis in patients infected with HIV.
Topics: Adult; Aged; AIDS-Related Opportunistic Infections; Dapsone; Drug Administration Schedule; Drug Ther | 1995 |
Thrice-weekly cotrimoxazole is better than weekly dapsone-pyrimethamine for the primary prevention of Pneumocystis carinii pneumonia in HIV-infected patients.
Topics: Adult; AIDS-Related Opportunistic Infections; Dapsone; Drug Administration Schedule; Drug Therapy, C | 1993 |
Prophylaxis for opportunistic infections among HIV-infected patients receiving medical care.
Topics: Adolescent; Adult; AIDS-Related Opportunistic Infections; Analysis of Variance; Anti-Infective Agent | 1998 |
A controlled trial of dapsone versus pyrimethamine-sulfadoxine for primary prophylaxis of Pneumocystis carinii pneumonia and toxoplasmosis in patients with AIDS.
Topics: Acquired Immunodeficiency Syndrome; Adult; Aged; AIDS-Related Opportunistic Infections; Anti-Infecti | 1997 |
Prophylaxis of AIDS-related opportunistic infections (OIs). Current status and future strategies.
Topics: Acquired Immunodeficiency Syndrome; Aerosols; Animals; Cryptococcosis; Cytomegalovirus Infections; D | 1991 |
12 other studies available for dapsone and Infection, Toxoplasma gondii
| Article | Year |
|---|---|
Innovative use of dapsone.
Topics: Adult; Anti-Infective Agents; Autoimmune Diseases; Child; Dapsone; Humans; Hypersensitivity; Jaundic | 2010 |
The treatment of experimental toxoplasmosis in rabbits.
Topics: Animals; Antimalarials; Dapsone; Pyrimethamine; Rabbits; Sulfamethazine; Sulfanilamide; Sulfanilamid | 1957 |
Sulphadimidine, pyrimethamine and dapsone in the treatment of toxoplasmosis in mice.
Topics: Animals; Antimalarials; Dapsone; Drug Therapy, Combination; Mice; Pyrimethamine; Sulfamethazine; Sul | 1957 |
[Hepatic lesions in experimental toxoplasmosis in mice: fatal acute form and chronic form treated by diaminodiphenylsulfone].
Topics: Animals; Dapsone; Liver; Mice; Sulfones; Toxoplasmosis | 1954 |
Diasone and promin as therapeutic agents in experimental toxoplasmosis.
Topics: Dapsone; Humans; Sulfones; Toxoplasmosis | 1951 |
Diasone, avlosulfon and sulphetrone as therapeutic agents in experimental toxoplasmosis.
Topics: Dapsone; Humans; Sulfones; Toxoplasmosis | 1952 |
Drugs for AIDS and associated infections.
Topics: Acquired Immunodeficiency Syndrome; AIDS-Related Opportunistic Infections; Amphotericin B; Antifunga | 1995 |
Toxoplasma gondii infection in advanced HIV infection.
Topics: Adult; AIDS-Related Opportunistic Infections; Dapsone; Encephalitis; Female; Humans; Male; Middle Ag | 1994 |
Pyrimethamine inhibits renal secretion of creatinine.
Topics: Adult; Creatinine; Dapsone; Drug Administration Schedule; Drug Interactions; Female; Humans; Kidney; | 1993 |
Preventing opportunistic infections.
Topics: Acyclovir; AIDS-Related Opportunistic Infections; Clarithromycin; Clindamycin; Clinical Trials as To | 1995 |
Optimizing PCP therapy.
Topics: Aerosols; AIDS-Related Opportunistic Infections; Antifungal Agents; Atovaquone; CD4 Lymphocyte Count | 1997 |
Twice-weekly dapsone-pyrimethamine for preventing PCP and cerebral toxoplasmosis.
Topics: Acquired Immunodeficiency Syndrome; Brain Diseases; Dapsone; Drug Administration Schedule; Drug Ther | 1991 |